Global Immunotherapy Market is expected to witness a Healthy Growth Rate of 13-14% by 2027 - Transforming Cancer Outcomes & Standard of Care for Advanced Malignancies

Cancer Immunotherapy refers to the medical treatment that uses the body's immune system to fight against cancer cells. It works by stimulating the immune system to recognize and attack cancer cells. The treatment either uses substances generated in the body or a laboratory to find cancer cells and fight against these cells. Immunotherapy is used to treat different types of cancer and can be used alone or combined with chemotherapy or other cancer treatments.

Cancer Immunotherapy Market: Key Market Trends

Cancer immunotherapy is rapidly advancing and has now been approved for the treatment of various cancers. Cancer immunotherapy plays an important role in the maintenance of the immune system by targeting the infectious agents that may cause cancer through the production of antibodies.

Some of the trends in Immunotherapy are as follows:

Combination Therapies: This methodology uses multiple immunotherapeutic drugs in the treatment of cancer. Some therapies have shown promising results in clinical trials and gaining popularity in the treatment of cancer. For instance, in April 2023, U.S. Food and Drug Administration (FDA) granted Astellas Pharma Inc. and Seagen Inc. accelerated approval for using PADCEV® with KEYTRUDA® as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) in the U.S. The indication is approved under accelerated approval based on tumor response rate and durability of response and for patients who are not eligible to receive cisplatin-containing chemotherapy.

Gene Editing: The advancement in gene editing technology is enabling the development of new immunotherapeutic drugs. For example, CRISPR-Cas9 has become a prominent therapeutic tool in cancer research and clinical trials.

Global Immunotherapy Market: Key Growth Drivers

Growing prevalence of cancer, an increasing geriatric population, and growing lifestyle changes are some of the key factors driving the growth of the global immunotherapy market. The rising number of clinical trials, and increasing efficacy and accuracy of the new therapies with fewer side effects compared to traditional treatments like chemotherapy, are expected to further drive the market's growth. The growing investments by the government in research and development activities, and the introduction of new treatment techniques like chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell transfer (ACT) therapy are other factors fueling its growth in the global immunotherapy market.

For instance,

In February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for using CARVYKTI® (ciltacabtagene autoleucel; cilia-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). This treatment will be given to patients, who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.

North America is Expected to Continue to Hold a Larger Share in the Global Immunotherapy Market

Geographically, North America accounts for a larger market share in the global immunotherapy market. This can be mainly attributed to an increasing number of cancer patients, rapid adoption of immunotherapy across U.S. oncology practices, well-developed healthcare infrastructures and the presence of key market players in the region. However, the Asia-Pacific region is anticipated to witness a strong growth in the upcoming years in the immunotherapy market, due to rising incidences of cancer and an increasing geriatric population in the region.

Competitive Landscape Analysis: Immunotherapy Market

Some of the key and well-established players operating in the global immunotherapy market are listed below: -
• Amgen Inc.
• Bayer AG
• Astellas Pharma Inc.
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer Inc.
• Eli Lily and Company
• Novartis AG
• Johnson & Johnson (Janssen Global Services LLC)
• Merck and Co. Inc.

Organic and Inorganic Growth Strategies Adopted by the leading Market Players to Establish Their Foothold in the Global Immunotherapy Market

All leading players operating in the immunotherapy market are adopting both organic and inorganic growth strategies such as upgrading with new technology, launching new products, collaborations, and acquisitions to garner higher market share.

For instance,

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) for the development, manufacture, and commercialization of next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

Growing cases of cancer, the introduction of newer treatment techniques such as chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, adoptive cell transfer (ACT) therapy are some of the major factors driving the growth of the immunotherapy market. However, the higher costs of immunotherapy and the presence of alternative affordable treatment like chemotherapy is expected to impede the growth of the immunotherapy market.

Get Detailed Insights on Immunotherapy Market with a Sample Report Copy @ https://meditechinsights.com/immunotherapy-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.